FDA: Benicar Linked to Celiac Disease, Enteropathy

December 13, 2013 Last Updated on April 29, 2015

Important Information

ClassAction.org is no longer reviewing claims for this case. The information here is for reference only. Up-to-date information and resources can be found here.

Comments |

At A Glance

This Alert Affects:
Patients who took Benicar (generic: olmesartan medoxomil) and developed gastrointestinal problems.
Side Effects:
Sprue-like enteropathy, celiac disease, villous atrophy, chronic diarrhea, substantial weight loss, and hospitalization.
Manufacturer:
Daiichi Sankyo Inc.
What is Benicar?
Benicar is used to treat high blood pressure and belongs to a group of drugs known as angiotensin II receptor blockers (ARBs).
FDA Warning:
In July 2013, the FDA issued a safety communication announcing a link between Benicar and sprue-like enteropathy, a condition that mimics celiac disease. The agency announced it would be updating the drug's labeling to reflect this risk.
Type of Lawsuit:
Mass Tort